Quest Diagnostics Incorporated (QDI.F)
| Previous close | 129.20 |
| Open | 130.95 |
| Bid | 131.10 x 30000 |
| Ask | 131.60 x 30000 |
| Day's range | 130.95 - 130.95 |
| 52-week range | 113.65 - 130.95 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 14.723B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 19.20 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.77 (2.15%) |
| Ex-dividend date | 08 Jul 2024 |
| 1y target est | N/A |
- Fortune
Employees are cheating on workplace drug tests at record rates—and legalized cannabis could be to blame
A rise in the use of recreational marijuana use in states that have legalized cannabis appears to be behind a spike in falsified workplace drug tests.
- Benzinga
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Cheating on drug tests among American workers has surged to its highest level in over 30 years, according to a lab report from Quest Diagnostics Inc (NASDAQ:DGX). The lab reported that approximately 31,000 out of 5.5 million drug tests showed signs of tampering in 2023. Dr. Suhash Harwani, senior director of science for workforce health solutions at Quest, highlighted the lengths some individuals go to subvert the drug-testing process. The steady rate of positive drug tests, combined with an inc
- Zacks
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
